Next Article in Journal
The Application of Heptamethine Cyanine Dye DZ-1 and Indocyanine Green for Imaging and Targeting in Xenograft Models of Hepatocellular Carcinoma
Next Article in Special Issue
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality
Previous Article in Journal
Immune Checkpoints as a Target for Colorectal Cancer Treatment
Previous Article in Special Issue
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
Open AccessReview

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Průmyslová 595, 25250 Vestec, Czech Republic
Int. J. Mol. Sci. 2017, 18(6), 1331; https://doi.org/10.3390/ijms18061331
Received: 26 May 2017 / Revised: 12 June 2017 / Accepted: 17 June 2017 / Published: 21 June 2017
(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
The therapy of different advanced-stage malignancies with monoclonal antibodies blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling has had an impressive long-lasting effect in a portion of patients, but in most cases, this therapy was not successful, or a secondary resistance developed. To enhance its efficacy in treated patients, predictive biomarkers are searched for and various combination treatments are intensively investigated. As the downregulation of major histocompatibility complex (MHC) class I molecules is one of the most frequent mechanisms of tumor escape from the host’s immunity, it should be considered in PD-1/PD-L1 checkpoint inhibition. The potential for the use of a PD-1/PD-L1 blockade in the treatment of tumors with aberrant MHC class I expression is discussed, and some strategies of combination therapy are suggested. View Full-Text
Keywords: PD-1; PD-L1; checkpoint blockade; MHC class I; tumor escape; cancer immunotherapy; biomarker; interferon gamma PD-1; PD-L1; checkpoint blockade; MHC class I; tumor escape; cancer immunotherapy; biomarker; interferon gamma
Show Figures

Graphical abstract

MDPI and ACS Style

Šmahel, M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Int. J. Mol. Sci. 2017, 18, 1331.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop